The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Estimated Market Size Of The Cellular Immunotherapy Market In 2026, And How Will Its Value Evolve By 2030?
The cellular immunotherapy market has experienced substantial expansion recently. This market is projected to expand from $6.56 billion in 2025 to $7.48 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 14.1%. Historically, this expansion has been driven by factors such as the achievements of initial CAR-T therapies, addressing unmet needs in oncology, an increase in research funding, obtaining regulatory approvals, and strong academic-industry partnerships.
The cellular immunotherapy market is anticipated to undergo significant expansion in the foreseeable future. Its valuation is predicted to ascend to $12.5 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.7%. This growth during the projection period stems from its extension into solid tumors, breakthroughs in nk cell therapy, the emergence of scalable manufacturing technologies, supportive regulatory frameworks, and augmented investment in oncology. Prominent developments expected throughout this period include the rapid proliferation of car-t cell therapies, the broadening scope of allogeneic cell therapies, their increased application in hematologic malignancies, continuous advancements in t cell engineering, and a surge in clinical trial engagements.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3435&type=smp
Which Drivers Are Supporting The Cellular Immunotherapy Market Growth?
The expanding incidence of cancer is expected to drive the growth of the cellular immunotherapy market going forward. Cancer is defined as a group of diseases characterized by the uncontrolled multiplication and spread of abnormal cells within the body. This rising prevalence is largely due to an aging population, various lifestyle factors, and improved screening and diagnosis techniques. Environmental exposures and genetic predispositions also play considerable roles in increasing the incidence rates. Cellular immunotherapy operates by enhancing the immune system’s response to specifically target tumor cells, which improves survival rates. This strategy, when combined with other treatments, has the potential to reduce both cancer incidence and recurrence. As an illustration, in March 2024, MAC Clinical Research, a UK-based cancer research organization, estimated that the number of individuals living with cancer in the United Kingdom is set to increase from approximately 3 million currently to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Hence, the increasing prevalence of cancer is a primary catalyst for the cellular immunotherapy market’s expansion.
What Are The Main Segments Within The Cellular Immunotherapy Market Segment Structure?
The cellular immunotherapy market covered in this report is segmented –
1) By Therapy: Tumor-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Cell Therapy
2) By Primary Indication: B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin lymphoma, Other Primary Indications
3) By Application: Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumor, Lung Cancer, Other Applications
Subsegments:
1) By Tumour-Infiltrating Lymphocyte (TIL) Therapy: Autologous TIL Therapy, Allogeneic TIL Therapy
2) By Engineered T Cell Receptor (TCR) Therapy: Alpha-Beta TCR Therapy, Gamma-Delta TCR Therapy
3) By Chimeric Antigen Receptor (CAR) T Cell Therapy: Autologous CAR T Cell Therapy, Allogeneic CAR T Cell Therapy, CAR T Cell Therapy For Solid Tumors, CAR T Cell Therapy For Hematologic Malignancies
4) By Natural Killer (NK) Cell Therapy: Autologous NK Cell Therapy, Allogeneic NK Cell Therapy, NK Cell Therapy With Engineered Modifications
Which Trends Are Guiding The Direction Of The Cellular Immunotherapy Market?
Leading companies in the cellular immunotherapy market are concentrating on developing technological advancements, such as immunotherapy itself, to enhance treatment efficacy and broaden applications. Their efforts are directed towards personalized medicine, combination therapies, and scalable manufacturing processes to improve patient outcomes. Immunotherapy involves a medical strategy that utilizes the body’s inherent immune system to combat diseases, especially cancer. This approach can either bolster immune responses or administer targeted therapies to heighten immune activity against specific cells. For instance, in December 2023, Max Healthcare Institute Limited, an India-based healthcare service provider company, was active in this domain. CAR-T cell therapy is recognized as a revolutionary cancer treatment, utilizing genetically engineered T cells to precisely target and eliminate cancer cells, thus offering a personalized methodology. It offers durable remission rates, particularly for resistant blood cancers, while concurrently minimizing harm to healthy tissues.
Who Are The Companies Participating In The Cellular Immunotherapy Market?
Major companies operating in the cellular immunotherapy market are Novartis International AG, Gilead Sciences Inc., Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co. Ltd, Green Cross Corp, AstraZeneca plc, Bristol Myers Squibb Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Adicet Bio Inc., ResTORbio Inc., Celyad SA, Merck KGaA, GlaxoSmithKline plc., Johnson & Johnson, Adaptimmune Therapeutics plc, AVROBIO Inc., Cellular Biomedicine Group Inc., Kite Pharma Inc., Juno Therapeutics Inc., Celgene Corporation, Bluebird Bio Inc., Tmunity Therapeutics Inc., Atara Biotherapeutics Inc., Fate Therapeutics Inc., Precision Biosciences Inc., Allogene Therapeutics Inc., CRISPR Therapeutics AG, Sangamo Therapeutics Inc., Intellia Therapeutics Inc., Editas Medicine Inc., Caribou Biosciences Inc., Mammoth Biosciences Inc., Synthego Corporation
Get The Full Cellular Immunotherapy Market Report:
https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report
Which Region Is The Leading Market For The Cellular Immunotherapy Market?
North America was the largest region in the cellular immunotherapy market in 2025. The regions covered in the cellular immunotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Cellular Immunotherapy Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report
Browse Through More Reports Similar to the Global Cellular Immunotherapy Market 2026, By The Business Research Company
Cellulars Immunotherapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report
Cancer Immunotherapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report
Allergy Immunotherapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/allergy-immunotherapy-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model